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Gender-Speciﬁc Differences in Adipose Distribution
and Adipocytokines Inﬂuence Adolescent
Nonalcoholic Fatty Liver Disease
Oyekoya T. Ayonrinde,1-4 John K. Olynyk,1-5 Lawrence J. Beilin,1,2,6 Trevor A. Mori,1,2 Craig E. Pennell,2,7
Nicholas de Klerk,2 Wendy H. Oddy,2 Peter Shipman,8 and Leon A. Adams1,2,9
Nonalcoholic fatty liver disease (NAFLD) is a predominantly adult-diagnosed disorder.
Knowledge regarding the epidemiology, phenotype, and metabolic risk factors, during
adolescence is limited. We sought to determine the prevalence, phenotype, and predictors
of NAFLD in 1170 community-based adolescents in the Western Australian Pregnancy
Cohort (Raine) Study (the Raine Cohort) who underwent a cross-sectional assessment that
included questionnaires, anthropometry, cardiovascular examinations, blood tests, and
abdominal ultrasound examinations. Among the 1170 adolescents assessed, the prevalence
of NAFLD was 12.8%. Females compared with males had a signiﬁcantly higher prevalence
of NAFLD (16.3% versus 10.1%, P 5 0.004) and central obesity (33.2% versus 9.9%, P <
0.05). The severity of hepatic steatosis was associated with the body mass index, waist cir-
cumference, subcutaneous adipose tissue thickness (SAT), serum leptin level, homeostasis
model assessment for insulin resistance score (P < 0.001 for all), and serum alanine amino-
transferase level (P < 0.005) in both genders, but it was associated with increasing visceral
adipose tissue thickness (VAT; P < 0.001) and decreasing serum adiponectin levels (P <
0.05) in males alone. Males and females with NAFLD had similar amounts of SAT (P >
0.05); however, in comparison with females with NAFLD, males with NAFLD had greater
VAT, a more severe metabolic phenotype with higher glucose levels and systolic blood pres-
sure and lower adiponectin and high-density lipoprotein cholesterol levels (P < 0.001 for
all), and greater measures of liver injury (alanine aminotransferase and aspartate amino-
transferase, P < 0.001 for all). Similarly, metabolic syndrome was more common in males
than females with NAFLD (24% versus 8%, P 5 0.01). Suprailiac skinfold thickness
predicted NAFLD independently of the body mass index, insulin resistance, and VAT.
Conclusion: Gender differences in adolescent NAFLD are related to differences in adipose
distribution and adipocytokines. The male phenotype of NAFLD is associated with more
adverse metabolic features and greater visceral adiposity than the female phenotype despite
the lower prevalence of NAFLD. (HEPATOLOGY 2011;53:800-809)
N
onalcoholic fatty liver disease (NAFLD) is a
predominantly adult-diagnosed liver disorder.
Predisposing factors for NAFLD may origi-
nate during early life. In adults, NAFLD increases the
risk of liver cirrhosis and forecasts an increased risk of
type 2 diabetes mellitus (type 2 diabetes) and atheroscler-
otic cardiovascular disease (CVD) and possibly reduced
life expectancy.1,2 Liver ﬁbrosis, including cirrhosis, has
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been reported in children with NAFLD.3,4 Therefore, a
diagnosis of NAFLD in childhood or adolescence heralds
potentially serious liver-related or metabolically related
outcomes in adulthood.
NAFLD is a global public health problem. The
prevalence of NAFLD is increased in ﬁrst-degree rela-
tives of individuals with NAFLD, particularly if they
are obese,5,6 and this suggests a potential cascade of
population risk. Unfortunately, NAFLD is often unrec-
ognized, particularly in children and adolescents.7
Serum alanine aminotransferase (ALT) levels are fre-
quently used to deﬁne NAFLD8-10; however, ALT is
relatively insensitive and nonspeciﬁc for NAFLD.11,12
The population prevalence of metabolic risk factors for
NAFLD in children and adolescents is increasing.13
The prevalence of NAFLD increases with age: at least
2.6% in children who are 4 to 12 years old,14 17.3%
in adolescents who are 15 to 19 years old,15 and up to
34% in adults.16 Although adolescent and childhood
NAFLD phenotypes share adiposity, dyslipidemia, and
insulin resistance with adult NAFLD, limited pheno-
typic and metabolic characterization has prevented an
in-depth analysis of these relationships.12,13
NAFLD is associated with metabolic syndrome.17-20
An Australian population–based adolescent cohort study
found an association between the highest ALT and
gamma-glutamyl transpeptidase (GGT) levels and high-
risk metabolic characteristics in 14-year olds.21 To gain
insight into the unique pathogenic mechanisms of child-
hood NAFLD and the population risk for NAFLD-related
progressive liver disease, type 2 diabetes, and CVD, we
determined the prevalence, anthropometric, cardiovascular,
and metabolic phenotype, and predictors of NAFLD in
the same cohort of adolescents at 17 years of age.
Patients and Methods
Seventeen-Year Survey
The study population comprised adolescents with a
mean age of 17 years (standard deviation ¼ 0.25 years)
who were participating in the Western Australian Preg-
nancy Cohort (Raine) Study (the Raine Cohort). The
background and methods of the Raine Cohort Study
have previously been described.22 The Raine Cohort is a
prospective cohort of pregnancy, childhood, and now
adolescence (http://www.rainestudy.org.au) and is repre-
sentative of the broader Western Australian population.23
Eighty-three percent of the original Raine Cohort
participants have been retained. All active members of
the Raine Cohort were invited to participate in the
17-year Raine follow-up survey, which was a cross-sec-
tional study conducted between July 2006 and June
2009. One thousand seven hundred seventy-one ado-
lescents participated in the 17-year survey; 66% under-
went a liver ultrasound evaluation, 71% underwent a
physical assessment, and 72% underwent a blood ex-
amination. Institutional ethics committee approval was
obtained from the human research ethics committee
of Princess Margaret Hospital for Children. Signed,
informed parental consent and adolescent assent were
obtained before participation in the study.
Assessment
The 17-year survey comprised detailed health ques-
tionnaires and anthropometric, abdominal ultrasound
(liver, subcutaneous, and visceral fat), cardiovascular,
and biochemical assessments. Information on alcohol
intake over the previous year was documented by self-
reporting and by the completion of a semiquantitative
food frequency questionnaire developed by the Com-
monwealth Scientiﬁc and Industrial Research Organi-
sation (Adelaide, Australia).24 Medications and a com-
prehensive medical history (including a history of fatty
liver or diabetes) were documented to exclude second-
ary causes of NAFLD and concomitant liver disease.
Anthropometric measurements [weight, height, waist
circumference, hip circumference, and skinfold thickness
(SFT)] and cardiovascular assessments [resting pulse
rate, systolic blood pressure (SBP), and diastolic blood
pressure (DBP)] were conducted by trained examiners.
Resting blood pressure readings were obtained with an
oscillometric sphygmomanometer (a Dinamap 8100
vital signs monitor, a Dinamap XL vital signs monitor,
or a Dinamap ProCare 100) set to automatically record
readings every 2 minutes with subjects supine. The av-
erage of the second and third readings was calculated.
SFT measurements were obtained from the anterior
abdominal wall, triceps, subscapular, and suprailiac
skinfolds with a skinfold caliper (Holtain Tanner/
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Whitehouse skinfold caliper, Holtain, Crosswell,
United Kingdom). The body mass index (BMI) was
calculated as the weight (kg) divided by the square of
the height (m2). Obesity was deﬁned according to age-
and gender-adjusted BMI criteria described by Cole
et al.25 and recommended by the International Obesity
Task Force. Waist-to-hip and waist-to-height ratios were
derived by the division of the waist circumference (cm)
by the hip circumference (cm) and height (cm), respec-
tively. Metabolic syndrome was deﬁned according to age-
and gender-speciﬁc criteria of the International Diabetes
Federation,26 which deﬁnes central obesity as a waist cir-
cumference greater than 80 cm in females and greater than
94 cm in males, a raised triglyceride level as greater than
1.7 mmol/L, a reduced high-density lipoprotein choles-
terol (HDL-C) level less than 1.03 mmol/L in males and
less than 1.29 mmol/L in females, a raised SBP as greater
than 130 mm Hg, a raised DBP as greater than 85 mm
Hg, and a raised fasting glucose level as greater than 5.6
mmol/L. The Tanner stage of puberty was described by
individual participants matching against charts with pic-
tures and descriptions of pubertal changes.
Ultrasonography
Trained ultrasonographers performed liver ultra-
sound with a Siemens Antares ultrasound machine
with a CH 6-2 curved array probe (Sequoia, Siemens
Medical Solutions, Mountain View, CA) according to
the protocol described by Hamaguchi and colleagues,27
which provides 92% sensitivity and 100% speciﬁcity
for the histological diagnosis of fatty liver. Abdominal
(subcutaneous and visceral) adipose thickness mea-
surements were performed with previously described
criteria28,29 that correlate closely with compartmental
adipose areas and cardiovascular and metabolic risk
factors.29,30 The visceral adipose tissue thickness
(VAT) was measured as the distance between the ante-
rior wall of the aorta and the internal face of the rectus
abdominis muscle perpendicular to the aorta. The sub-
cutaneous adipose tissue thickness (SAT) was measured
as the thickness of the fat tissue between the skin-fat
interface and the linea alba; SAT compression was
avoided. A single specialist radiologist (P.S.) who was
blinded to the clinical and laboratory characteristics of
the subjects interpreted the ultrasound images. Scores
of 0 to 3, 0 to 2, and 0 to 1 were determined from
captured images for liver echotexture (bright liver and
hepatorenal echo contrast), deep attenuation (dia-
phragm visibility), and vessel blurring (intrahepatic
vessel visibility), respectively. The diagnosis of fatty
liver required a total score of at least 2, which included
an echotexture score of at least 1. Hepatic fatty inﬁl-
tration (steatosis) severity was classiﬁed by the total
fatty liver score as 0 to 1 (no fatty liver), 2 to 3 (mild
fatty liver), or 4 to 6 (moderate to severe fatty liver).
The intraclass correlation coefﬁcient was 0.93 for SAT
[95% conﬁdence interval (CI) ¼ 0.93-0.93] and 0.94
for VAT (95% CI ¼ 0.94-0.95), whereas the intraob-
server reliability (j statistic) for fatty liver was 0.78
(95% CI ¼ 0.73-0.88). Adolescents with sonographic
fatty liver and a self-reported weekly alcohol intake of
less than 140 g for males and 70 g for females over the
previous 12 months were classiﬁed as having NAFLD.
Testing for hepatitis B or C virus infections was not per-
formed because notiﬁcation rates for hepatitis B and C
virus infections were on average less than 24/100,000
and 23/100,000, respectively, for Western Australian
teenagers between the ages of 15 and 19 years over the
study period (personal communication, Western Austra-
lian Notiﬁable Infectious Diseases Database, Epidemiol-
ogy and Surveillance Program, Communicable Disease
Control Directorate, Department of Health of Western
Australia, July 27, 2010).
Biochemistry
Laboratory assessments were performed with venous
blood samples taken from an antecubital vein after an
overnight fast. Serum glucose, insulin, ALT, aspartate
aminotransferase (AST), GGT, triglyceride, total cho-
lesterol, HDL-C, low-density lipoprotein cholesterol
(LDL-C), ferritin, transferrin saturation, highly sensi-
tive C-reactive protein (CRP), adiponectin, and leptin
levels were assayed. All laboratory assays were per-
formed at an accredited central laboratory (Pathwest
Laboratories, Perth, Western Australia, Australia).
Serum ALT levels greater than 40 U/L in males and
greater than 30 U/L in females were considered ele-
vated in accordance with the reference laboratory. The
homeostasis model assessment for insulin resistance
(HOMA-IR) score was calculated as follows:
HOMA-IRscore ¼ ½Fasting insulin ðlU=mLÞ
Fasting glucose ðmmol=LÞ=22:5
Statistical Analysis
Continuous descriptive data are presented as means
and standard deviations for normally distributed data
and as medians and interquartile ranges (IQRs) for
nonnormally distributed data. Categorical variables are
reported as percentages. The main outcome variables
were the presence or absence of NAFLD and the sever-
ity of sonographic fatty liver. Thus, the analysis was
limited to adolescents who had undergone abdominal
ultrasound examinations; they are henceforth called the
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cohort. Because of signiﬁcant gender differences in
NAFLD prevalence, demographic, anthropometric, and
biochemical data for males and females were analyzed
separately. Differences in continuous variables between
adolescents with or without NAFLD and between stea-
tosis severities or genders were computed with an inde-
pendent t test or one-way analysis of variance with the
Bonferroni adjustment for normally distributed variables
and with nonparametric analysis (the Mann-Whitney U
test or Kruskall-Wallis test) for nonnormally distributed
data. Differences between categorical variables were
determined with the Pearson chi-square test or Fisher’s
exact test. Adiponectin levels below the 10th percentile
were considered reduced. All P values were reported as
two-sided and were interpreted at the 5% level of sig-
niﬁcance. Multiple logistic regression analysis was used
to calculate the odds of NAFLD prevalence from indi-
vidual baseline characteristics. Data were analyzed with
SPSS, version 15.0 (SPSS, Chicago, IL).
Results
Prevalence of NAFLD
Among the 1170 adolescents (51% male) assessed
by ultrasound, the prevalence of fatty liver was 15.6%
(182/1170). After the exclusion of 32 adolescents (27
females and 5 males) who consumed excessive quantities
of alcohol, the prevalence of NAFLD was 12.8% (150/
1170). NAFLD was more prevalent in females than
males (16.3% versus 10.1%, P ¼ 0.004). The preva-
lence of NAFLD by steatosis severity in females versus
males was 2.2% versus 3.1% for moderate to severe ste-
atosis, 14.1% versus 7.0% for mild steatosis, and
83.7% versus 89.9% for no steatosis (P < 0.001). The
prevalence of NAFLD increased with BMI: 4%, 15%,
and 65% for normal-weight, overweight, and obese
males, respectively, and 10%, 29%, and 57% for nor-
mal-weight, overweight, and obese females, respectively.
None of the participants had a previous diagnosis of
NAFLD or type 2 diabetes or a history of insulin therapy.
Most participants (98% of males and 99% of females)
were pubertal or postpubertal according to the Tanner
scale. The Tanner stage of puberty was not associated
with the presence or absence of NAFLD (P > 0.05).
Adipose Distribution in the Cohort
According to International Diabetes Federation cri-
teria, the prevalence of central obesity determined by
waist circumference was 21.4%. More females than
males had central obesity (33.2% versus 9.9%, P <
0.05). There was also a gender difference in abdominal
fat distribution. Females had greater mean SAT than
males (20.8 6 11.1 versus 14.6 6 10.5 mm, P <
0.001); however, males had greater mean VAT than
females (35.2 6 10.7 versus 29.8 6 8.9 mm, P <
0.001). The subcutaneous to visceral adipose tissue ratio
(SVAR) was higher in females versus males (0.72 6
0.52 versus 0.42 6 0.41, P < 0.001). Waist circumfer-
ence was more positively correlated with subcutaneous
adiposity (suprailiac SFT or SAT: r ¼ 0.80 or 0.78 in
males and r ¼ 0.66 or 0.71 in females, P < 0.001 for
both) than visceral adiposity (r ¼ 0.26 and 0.09 for
males and females, respectively, P < 0.001); that is,
waist circumference reﬂected SATmore than VAT.
Despite signiﬁcant gender differences in central obe-
sity, SAT, and VAT, there were similar proportions of
overweight and obese individuals between genders
when BMI categories were used (77.0%, 14%, and
9% of normal-weight, overweight, and obese females,
respectively, and 77.3%, 14.2%, and 8.5% of normal-
weight, overweight, and obese males, respectively).
Anthropometry, Adipose Distribution, and
Presence and Severity of Steatosis
Males and females with NAFLD had greater adipos-
ity [including body weight, BMI, waist circumference,
waist/hip ratio, waist/height ratio, and subcutaneous
adiposity (SAT and SFT)] than those without NAFLD
(P < 0.005). Apart from the waist/hip ratio in females,
adiposity measures were associated with increasing sever-
ity of steatosis (P < 0.05; Fig. 1 and Table 1).
Males with NAFLD had signiﬁcantly higher
weights, BMIs, waist circumferences, and waist/hip
ratios than females with NAFLD (P < 0.05); however,
subcutaneous adiposity was similar in males and
females with NAFLD. In contrast, males with NAFLD
had signiﬁcantly greater VAT than females with
NAFLD (40.8 versus 31.1 mm, P < 0.001). VAT was
associated with steatosis severity in males only (P <
0.001; Fig. 1 and Table 1). The prevalence of moder-
ate to severe steatosis was higher with elevated VAT
versus nonelevated VAT in males (9.3% versus 0.4%,
P < 0.05) but not in females (2.5% versus 1.7%, P ¼
0.18). Correspondingly, SVAR was higher in females
with NAFLD versus males with NAFLD (median ¼
0.70 and IQR ¼ 0.52-1.18 for females, median ¼
0.53 and IQR ¼ 0.31-0.96 for males, P ¼ 0.02).
Relationship Between NAFLD and
Metabolic Risk Factors
Metabolic syndrome was more prevalent in males
than females with NAFLD (24% versus 8%, P ¼
0.001). The severity of the components of the meta-
bolic syndrome worsened with increasing severity of
steatosis, particularly in males (Table 1 and Fig. 2).
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Cardiovascular Parameters and NAFLD
Males with NAFLD had higher SBPs and resting
pulse rates than males without NAFLD; however, this
relationship was not evident in females. Also, males
with NAFLD had signiﬁcantly higher SBPs than
females with NAFLD (P < 0.05), and in males, SBP
was associated with increasing severity of NAFLD (P <
0.05; Table 1 and Fig. 2).
Markers of Liver Injury and Inﬂammation
Adolescents with NAFLD had higher measures of
liver injury (ALT, AST, and GGT) and inﬂammation
(CRP) than those without NAFLD. Males with
NAFLD had signiﬁcantly higher serum ALT, AST,
GGT, and ferritin levels than females with NAFLD.
Serum ALT and GGT levels increased with increasing
steatosis severity (P < 0.05) in both genders (Table 1).
Insulin Resistance and Lipids
Insulin resistance (HOMA-IR and fasting insulin) and
lipid abnormalities (fasting triglycerides and HDL-C)
were more severe in adolescents with NAFLD versus
those without NAFLD. Males (but not females) with
NAFLD had higher fasting glucose levels than those
without NAFLD (in males, 5.0 versus 4.8 mmol/L, P <
0.05; in females, 4.6 versus 4.6 mmol/L, P > 0.05).
Males with NAFLD had signiﬁcantly lower HDL-C
levels than females with NAFLD (Table 1). Serum insu-
lin levels and HOMA-IR scores increased and HDL-C
levels decreased with increasing steatosis severity (P <
0.05) in both genders.
Adipocytokines
Leptin. Females in the cohort had higher levels of
leptin in comparison with males in the presence or
Fig. 1. Adipose distribution and adipocytokine levels in adolescents with NAFLD differ according to gender. Males have greater VAT and lower
adiponectin levels than females. Females have greater SAT and higher leptin levels than males. The black bars represent subjects without NAFLD,
the dark gray bars represent subjects with mild hepatic steatosis, and the light gray bars represent subjects with moderate to severe hepatic ste-
atosis. The box plots display median values and 25th and 75th percentiles; the whiskers represent the 5th and 95th percentiles.
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absence of NAFLD (Table 1). Serum leptin levels were
higher in males and females with NAFLD versus those
without NAFLD (P < 0.05), and this was independ-
ent of BMI or waist circumference in males. Leptin
levels were associated with steatosis severity in males
and females. Leptin levels were also more strongly
Fig. 2. Association between the components of metabolic syndrome and the severity of ultrasound-diagnosed hepatic steatosis in female and
male patients with NAFLD. The black bars represent subjects without NAFLD, the dark gray bars represent subjects with mild hepatic steatosis,
and the light gray bars represent subjects with moderate to severe hepatic steatosis. The box plots display median values and 25th and 75th
percentiles; the whiskers represent the 5th and 95th percentiles.
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correlated with subcutaneous adiposity (r ¼ 0.72 in
males and r ¼ 0.58 in females, P < 0.001 for suprail-
iac SFT) than visceral adiposity (r ¼ 0.28 in males
and r ¼ 0.16 in females, P < 0.005 for VAT).
Adiponectin. Males had lower adiponectin levels
than females in the presence or absence of NAFLD
(Table 1 and Fig. 1). Males and females with NAFLD
had lower serum adiponectin levels than those without
NAFLD, and this was independent of BMI and waist
circumference in males. Serum adiponectin levels were
inversely associated with steatosis severity in males
(P < 0.01) but not females (P ¼ 0.4; Fig. 1). Serum
adiponectin was negatively correlated with suprailiac
SFT in males and females (r ¼ 0.14, P < 0.05) and
with VAT in males only (r ¼ 0.12, P ¼ 0.01).
Independent Predictors of NAFLD
Multiple regression analysis, which included gender,
VAT, HOMA-IR, serum leptin, adiponectin, and
HDL-C, found that suprailiac SFT (odds ratio ¼
1.14, P < 0.001, 95% CI ¼ 1.11-1.17) and serum
ALT (odds ratio ¼ 1.02, P ¼ 0.01, 95% CI ¼ 1.01-
1.04) were signiﬁcant and independent predictors of
NAFLD in the cohort at the age of 17 years. Gender
was not independently associated with NAFLD despite
NAFLD being more common in females. Gender-spe-
ciﬁc analysis found that independent predictors of
NAFLD at the age of 17 years in males were suprailiac
SFT (odds ratio ¼ 1.14, P < 0.001, 95% CI ¼ 1.10-
1.19) and serum ALT (odds ratio ¼ 1.04, P ¼ 0.002,
95% CI ¼ 1.01-1.06), whereas in females, suprailiac
SFT alone was signiﬁcant (odds ratio ¼ 1.13, P <
0.001, 95% CI ¼ 1.10-1.17). Although waist circum-
ference and BMI were independent predictors of
NAFLD in males (odds ratio ¼ 1.13, P < 0.001, and
odds ratio ¼ 1.36, P < 0.001, respectively) and
females (odds ratios ¼ 1.08, P < 0.001, and odds
ratio ¼ 1.24, P < 0.001, respectively), neither remained
signiﬁcant with adjustments for suprailiac SFT.
Discussion
NAFLD was common (13%) in this population-
based study of adolescents. There were marked gender
differences in the prevalence, anthropometric and meta-
bolic phenotype, adipose distribution, degree of liver
injury, and adipocytokine levels in adolescents with
NAFLD that may have important implications for the
future risk of progressive NAFLD and the development
of metabolic syndrome, type 2 diabetes, and CVD.
NAFLD was approximately 1.5 times more preva-
lent in females than males; this contrasts with other
reports that have found NAFLD to be more prevalent
in males.16-18,20 The difference can be explained by
the relatively large proportion of females with central
obesity, the population-based nature of our study, and
the nonrequirement for raised ALT levels for partici-
pant recruitment. Using a raised ALT level as an inclu-
sion criterion would have introduced a gender recruit-
ment bias because ALT levels are higher in males than
females.10 Furthermore, 90% of males and 91% of
females with fatty liver in our cohort had normal ALT
levels, and this indicates that the majority of the subjects
would have been missed if we had relied upon ALT.
The gender differences in NAFLD prevalence were
associated with signiﬁcant differences in adipose distri-
bution and metabolic parameters, including adipocyto-
kine levels. Males with NAFLD had the same SAT but
had greater VAT than females with NAFLD, and this
resulted in a signiﬁcantly lower SVAR in males (Table
1). Correspondingly, male NAFLD was associated with
higher levels of ALT, a more severe metabolic pheno-
type with higher SBP, a greater risk of metabolic syn-
drome, and lower adiponectin levels than female
NAFLD despite similar insulin resistance rates and
similar rates of abdominal obesity. These ﬁndings may
be explained by functional differences in visceral adi-
pose tissue versus subcutaneous adipose tissue. Visceral
adipose tissue is inﬁltrated with inﬂammatory cells and
releases inﬂammatory cytokines such as interleukin-6
(IL-6) and tumor necrosis factor a. Visceral adipose
tissue is more insulin-resistant and has greater lipolysis
rates and release of potentially hepatotoxic free fatty
acids.31-33 Visceral fat has been demonstrated to be
associated with advanced nonalcoholic steatohepatitis
(NASH) and ﬁbrosis after adjustments for insulin resist-
ance,34 and this suggests that male adolescents are at
higher risk of developing liver disease than female adoles-
cents. Interestingly, males are overrepresented in histologi-
cal series of pediatric NASH patients, and male gender has
been associated with portal ﬁbrosis in pediatric
NAFLD.15,35,36 Gender has not been a reproducible risk
factor for advanced NASH in adults; however, this may be
due to the grouping of premenopausal and postmenopausal
women, which may obscure any sex hormonal effect. The
relationship between hepatic ﬁbrosis and regional fat distri-
bution in adults differs according to gender and, in females,
menopausal status, so central adiposity is associated with a
higher risk of ﬁbrosis in men and postmenopausal women
than in premenopausal women.37
Interactions between sex hormones, adipocytokines,
insulin resistance, and adipose distribution may explain
the differences in the gender distribution of NAFLD. In
comparison with visceral adipose tissue, subcutaneous
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adipose tissue adipocytes have a higher density of estro-
gen receptors and leptin release. Greater leptin and
estrogen production in females may protect against vis-
ceral adipose tissue accumulation and NASH, possibly
by inhibiting IL-6.31 Visceral adipose tissue adipocytes
exhibit greater insulin resistance, expression of androgen
receptors, and adiponectin and IL-6 release than subcu-
taneous adipose tissue adipocytes.31-33,38
Subcutaneous and visceral compartmentalization of
adipose tissue is inﬂuenced by age and gender. Visceral
adipose tissue accumulates more rapidly with age and
weight gain in males and postmenopausal females than
in younger females.39,40 Approximately 90% of ab-
dominal fat in children is subcutaneous adipose tissue,
with intra-abdominal adipose tissue representing less
than 10% of total abdominal adiposity.41 With advanc-
ing age, visceral adipose tissue increases and accounts
for 10% to 20% of total fat in men but a smaller pro-
portion (up to 8%) in women.33 Because the liver
receives portal venous blood containing free fatty acids
and cytokines secreted by visceral adipocytes, which
may contribute to insulin resistance,31 an increased
prevalence and severity of NAFLD could be expected,
particularly in males, with increasing age, abdominal
obesity, VAT, and androgenic activity in adults.42
Our observation that SAT was similar in males and
females with NAFLD and was predictive of NAFLD
independently of BMI, VAT, and HOMA-IR implies a
role for compartmental fat distribution, including sub-
cutaneous fat, in the development of NAFLD. We
found subcutaneous fat to be associated with the sever-
ity of hepatic steatosis. Conventionally, visceral adiposity
is considered to be more important than subcutaneous
adiposity with respect to the risk of NAFLD.43-45 How-
ever, many studies have predominantly focused on
adults and overweight and obese populations or have
not stratiﬁed their analyses by gender. Furthermore,
ultrasound-measured abdominal SAT (but not VAT)
was the best predictor of insulin resistance in a study
of childhood obesity,46 and SFT has been shown to be
more sensitive for obesity than BMI.47 Similarly, SAT
predicts insulin resistance independently of VAT in
adults.48 We observed suprailiac SFT to be the strongest
predictor of a diagnosis of adolescent NAFLD. Although
subcutaneous adiposity predicts adolescent NAFLD, it is
plausible that greater VAT reﬂects an increased risk for
NASH (orchestrated by hypoadiponectinemia) as part of
an adverse metabolic risk proﬁle.
In conclusion, NAFLD is relatively common in
adolescents. The gender difference in the prevalence
and severity of NAFLD is related to differences in
the prevalence of central obesity, adipose distribution,
adipocytokines, and sex hormones. SAT may play an
important role in determining the development of he-
patic steatosis, with VAT being related to the severity
of liver injury and metabolic disturbance. In our
study, males had greater VAT, greater steatosis sever-
ity, lower adiponectin levels, and more metabolic risk
factors than females, whereas females had a higher
prevalence of NAFLD with greater SAT, higher leptin
levels, and fewer metabolic risk factors than males.
The high prevalence of metabolic risk factors, includ-
ing insulin resistance, abdominal obesity, and meta-
bolic syndrome, in adolescents with NAFLD under-
scores the potential risk for long-term hepatic
lipotoxicity, liver disease, type 2 diabetes, and CVD.
Suprailiac SFT, a subcutaneous adiposity measure, is a
stronger predictor of adolescent NAFLD than VAT,
BMI, waist circumference, HOMA-IR, or serum ALT.
Future studies examining the development of NAFLD
should incorporate gender-stratiﬁed analyses adjusted
for subcutaneous adiposity. It is likely that the pathoge-
nesis of NAFLD in males and females differs in terms
of genetic and hormonal inﬂuences on compartmental
adipose deposition, including the liver.
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